Ampio pharmaceuticals announces pricing of $22.5 million registered direct offering

Englewood, colo., dec. 13, 2021 /prnewswire/ -- ampio pharmaceuticals, inc. (nyse american: ampe), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced that it has entered into definitive agreements with institutional investors for the purchase and sale of 25,000,000 shares of the company's common stock ( the "shares") and warrants to purchase 15,000,000 shares of the company's common stock (the "warrants" and, together with the shares, the "securities") at a combined purchase price of $0.90 per share in a registered direct offering.
AMPE Ratings Summary
AMPE Quant Ranking